ZYMEWORKS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ZYMEWORKS INC. (ZYME) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.83%, a 16.38% decline year-over-year.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.58%, a 14.21% increase year-over-year.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.01%, a 4.97% increase year-over-year.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.82%, a 107.61% increase year-over-year.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.32%, a 6.93% increase from fiscal 2024.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.04%, a 2.54% increase from fiscal 2023.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.94%, a 85.85% increase from fiscal 2022.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.12%, a 107.84% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.90% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 3.83% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.32% 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 4.43% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.49% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 4.58% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.04% 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 4.03% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 4.08% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.01% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 3.94% 10-K · filed 2026-03-02 | |||
| 2023-09-30 | 3.86% 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | 3.82% 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | 2.12% 10-K · filed 2025-03-05 | |||
| 2022-09-30 | 1.98% 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 1.89% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 1.84% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 1.02% 10-K · filed 2024-03-06 | |||
| 2021-09-30 | 0.98% 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | 0.66% 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |